Soihtu DTx
Accelerator
Soihtu DTx develops prescription video game-based digital therapeutics for major depressive disorder.
Founded
2023Soihtu DTx develops prescription video game-based digital therapeutics for major depressive disorder.
Soihtu DTx's flagship product is an immersive video game-based digital therapeutic designed to treat major depressive disorder. The intervention combines adaptive cognitive training with immersive and interactive therapeutic content delivered through a proprietary medical engine.
The product offers closed-loop theragnostics and personalized treatment adaptation, aiming to provide an engaging alternative for patients resistant to conventional therapies. The company is advancing the product toward FDA 510(k) premarket notification.
The global digital therapeutics market is expanding rapidly, with prescription digital therapeutics gaining regulatory approval and reimbursement pathways. Soihtu DTx targets the major depressive disorder segment, where significant unmet need exists for patients resistant to conventional antidepressant therapies.
The company's FDA 510(k) pathway and partnerships with regulatory strategists position it to capture market share in the emerging prescription DTx space. Its game-based approach addresses both efficacy and patient engagement, key barriers to adoption in mental health treatment.
Soihtu DTx combines decades of entertainment game production prowess with clinical expertise and neuroscience research, creating a unique position in the digital therapeutics market. The company's proprietary medical engine delivers unprecedented treatment personalization and closed-loop theragnostics.
As a founding member of the BrainTech Alliance and participant in the 2026 Techstars and Northwestern Medicine Healthcare Accelerator, Soihtu DTx benefits from strong networks in brain health innovation and healthcare enterprise partnerships.
